What question did this study set out to answer?

To review the pathophysiological mechanisms underpinning inflammatory bowel disease and evaluate the shift from single-pathway therapies to integrated, multitarget therapeutic approaches.

August 19, 2026MedCommOpen Access

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

View Full Paper

Ask AI

Bookmark

Authors

APAndrea PapaitUniversità Cattolica del Sacro Cuore ACAnna CargnoniFondazione Poliambulanza Istituto Ospedaliero FSFranco ScaldaferriUniversità Cattolica del Sacro Cuore

Discussion

Member takes

Overview

Narrative review reveals therapeutic limits and mechanistic drivers in inflammatory bowel disease, highlighting a necessary paradigm shift toward multitarget strategies.

Key Points

To review the pathophysiological mechanisms underpinning inflammatory bowel disease and evaluate the shift from single-pathway therapies to integrated, multitarget therapeutic approaches.
Synthesized molecular and cellular evidence linking innate and adaptive immune networks, epithelial barrier dysfunction, and gut microbiota perturbations in disease pathogenesis.
Critically analyzed clinical efficacy and pathway restrictions of current biologics and small molecules, while assessing emerging nonimmune and cellular therapies.
Current single-pathway biologics and Janus kinase inhibitors fail to produce durable remission in 30% to 40% of patients, permitting progression to stricturing, fistulizing, or transmural complications.
Novel interventions targeting nonimmune pathways—including microRNA-124 regulation, fecal microbiota transplantation, and mesenchymal stromal cell repair—address multidimensional disease drivers.
Combining complementary treatment strategies tailored through molecular and cellular profiling represents the leading paradigm to overcome monotherapy resistance.

Cite This Study

Papait et al. (2026) studied this question.

synapsesocial.com/papers/6a85638803308d306e2d6cf0 https://doi.org/10.1002/mco2.70914

View Full Paper

Ask AI

Bookmark

August 19, 2026MedCommOpen Access

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

View Full Paper

Ask AI

Bookmark

Authors

APAndrea PapaitUniversità Cattolica del Sacro Cuore ACAnna CargnoniFondazione Poliambulanza Istituto Ospedaliero FSFranco ScaldaferriUniversità Cattolica del Sacro Cuore

Discussion

Member takes

Overview

Narrative review reveals therapeutic limits and mechanistic drivers in inflammatory bowel disease, highlighting a necessary paradigm shift toward multitarget strategies.

Key Points

To review the pathophysiological mechanisms underpinning inflammatory bowel disease and evaluate the shift from single-pathway therapies to integrated, multitarget therapeutic approaches.
Synthesized molecular and cellular evidence linking innate and adaptive immune networks, epithelial barrier dysfunction, and gut microbiota perturbations in disease pathogenesis.
Critically analyzed clinical efficacy and pathway restrictions of current biologics and small molecules, while assessing emerging nonimmune and cellular therapies.
Current single-pathway biologics and Janus kinase inhibitors fail to produce durable remission in 30% to 40% of patients, permitting progression to stricturing, fistulizing, or transmural complications.
Novel interventions targeting nonimmune pathways—including microRNA-124 regulation, fecal microbiota transplantation, and mesenchymal stromal cell repair—address multidimensional disease drivers.
Combining complementary treatment strategies tailored through molecular and cellular profiling represents the leading paradigm to overcome monotherapy resistance.

Cite This Study

Papait et al. (2026) studied this question.

synapsesocial.com/papers/6a85638803308d306e2d6cf0 https://doi.org/10.1002/mco2.70914

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark